0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TLR3

TLR3

Brief Information

Name:Toll like receptor 3
Target Synonym:CD283,TLR3,Toll Like Receptor 3,Toll-Like Receptor 3,CD283 Antigen,IIAE2
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
TL3-H5253 Human Human TLR3 Protein, Fc Tag (MALS verified)
TL3-H5253-structure
TL3-H5253-sds

Part of Bioactivity data

TL3-H5253-MALS-HPLC
Human TLR3, Fc Tag (Cat. No. ) MALS images

The purity of Human TLR3, Fc Tag(Cat. No. TL3-H5253) was more than 90% and the molecular weight of this protein is around 265-285 kDa verified by SEC-MALS.

  • Background
    Toll-like receptor 3 (TLR3) is also known as CD283, which belongs to the Toll-like receptor family which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 / CD283 contains 22 LRR (leucine-rich) repeats, 1 LRRCT domain, 1 LRRNT domain and 1 TIR domain. TLR3 is expressed at high level in placenta and pancreas and also detected in CD11c+ immature dendritic cells. CD283 / TLR3 is only expressed in dendritic cells. TLR3 is the TLR that is expressed most strongly in the brain, especially in astrocytes, glia, and neurons. CD283 / TLR-3 is the key component of innate and adaptive immunity. TLR3 / CD283 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. TLR3 acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Defects in TL-R3 are associated with herpes simplex encephalitis type 2 (HSE2).
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Synonym Name

TLR3,CD283,IIAE2

Background

Toll-like receptor 3 (TLR3) is also known as CD283, which belongs to the Toll-like receptor family which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 / CD283 contains 22 LRR (leucine-rich) repeats, 1 LRRCT domain, 1 LRRNT domain and 1 TIR domain. TLR3 is expressed at high level in placenta and pancreas and also detected in CD11c+ immature dendritic cells. CD283 / TLR3 is only expressed in dendritic cells. TLR3 is the TLR that is expressed most strongly in the brain, especially in astrocytes, glia, and neurons. CD283 / TLR-3 is the key component of innate and adaptive immunity. TLR3 / CD283 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. TLR3 acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Defects in TL-R3 are associated with herpes simplex encephalitis type 2 (HSE2).

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Rintatolimod Approved Hemispherx Biopharma Ampligen, Rintamod Argentina Fatigue Syndrome, Chronic Hemispherx Biopharma 2017-01-01 HIV Infections; Influenza, Human; Fatigue Syndrome, Chronic; HIV Seropositivity Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
H1N1 seasonal influenza virus vaccine (Vaxart) VXA-A1.1 Phase 2 Clinical Vaxart Influenza A virus infections; Influenza, Human Details
CNTO-5 CNTO-5 Phase 1 Clinical Morphosys Ag Inflammation Details
PGV-001 PGV-001 Phase 1 Clinical Genentech Inc, Icahn School Of Medicine At Mount Sinai Neoplasms Details
Monovalent norovirus Vaccine (Vaxart) VXA-G1-1-NN; VXA-G1.1-NN Phase 2 Clinical Vaxart Caliciviridae Infections Details
Respiratory syncytial virus vaccine oral (Vaxart) VXA-RSV-f Phase 1 Clinical Vaxart Respiratory Syncytial Virus Infections Details
CNTO-3157 PRV-300; CNTO-3157; JNJ-42915925 Phase 2 Clinical Centocor Ortho Biotech, Morphosys Ag Colitis, Ulcerative; Asthma Details
TR-987 Z-101; GLYC-101; MG-3601 Phase 2 Clinical Kazia Therapeutics Wounds and Injuries; Varicose Ulcer Details
Poly ICLC (Oncovir) Phase 2 Clinical National Institutes Of Health, Yamasa Corp Pancreatic Neoplasms; Melanoma; Glioma; Uterine Cervical Dysplasia; Colorectal Neoplasms; Prostatic Neoplasms; Influenza, Human; Mesothelioma; Cytomegalovirus Infections; HIV Infections; Glioblastoma; Lymphoma, Large B-Cell, Diffuse; Coronavirus Disease 2019 (COVID-19); Ovarian Neoplasms; Liver Neoplasms; Lymphoma, B-Cell; Smallpox Details

This web search service is supported by Google Inc.

totop